DE602004028841D1 - Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c - Google Patents
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis cInfo
- Publication number
- DE602004028841D1 DE602004028841D1 DE602004028841T DE602004028841T DE602004028841D1 DE 602004028841 D1 DE602004028841 D1 DE 602004028841D1 DE 602004028841 T DE602004028841 T DE 602004028841T DE 602004028841 T DE602004028841 T DE 602004028841T DE 602004028841 D1 DE602004028841 D1 DE 602004028841D1
- Authority
- DE
- Germany
- Prior art keywords
- flavividraic
- diseases
- treatment
- pentofuranonucleoside
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 PURIN NUCLEOSIDE Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 239000002777 nucleoside Substances 0.000 title 1
- XZLIYCQRASOFQM-UHFFFAOYSA-N 5h-imidazo[4,5-d]triazine Chemical class N1=NC=C2NC=NC2=N1 XZLIYCQRASOFQM-UHFFFAOYSA-N 0.000 abstract 1
- 241000710831 Flavivirus Species 0.000 abstract 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 241000710778 Pestivirus Species 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/044—Pyrrole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49021603P | 2003-07-25 | 2003-07-25 | |
| PCT/IB2004/002703 WO2005009418A2 (en) | 2003-07-25 | 2004-07-26 | Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004028841D1 true DE602004028841D1 (de) | 2010-10-07 |
Family
ID=34102969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004028841T Active DE602004028841D1 (de) | 2003-07-25 | 2004-07-26 | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20050075309A1 (de) |
| EP (1) | EP1658302B1 (de) |
| JP (1) | JP2007501185A (de) |
| KR (1) | KR20060084845A (de) |
| CN (1) | CN1852915A (de) |
| AT (1) | ATE478886T1 (de) |
| AU (1) | AU2004258750A1 (de) |
| BR (1) | BRPI0412849A (de) |
| CA (1) | CA2533367C (de) |
| DE (1) | DE602004028841D1 (de) |
| DK (1) | DK1658302T3 (de) |
| ES (1) | ES2351603T3 (de) |
| NO (1) | NO20060914L (de) |
| PL (1) | PL1658302T3 (de) |
| PT (1) | PT1658302E (de) |
| RU (1) | RU2006105640A (de) |
| WO (1) | WO2005009418A2 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2345658A1 (de) * | 2003-05-30 | 2011-07-20 | Pharmasset, Inc. | Modifizierte fluorinierte Nukleosidanaloga |
| PT1658302E (pt) * | 2003-07-25 | 2010-10-25 | Centre Nat Rech Scient | Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c |
| WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
| CN101023094B (zh) * | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
| RU2433124C2 (ru) * | 2004-09-14 | 2011-11-10 | Фармассет, Инк. | Способ получения 2'-фтор-2'-алкилзамещенных или других замещенных рибофуранозилпиримидинов и пуринов и их производных |
| CA2600359A1 (en) * | 2005-03-09 | 2006-09-09 | Idenix (Cayman) Limited | Nucleosides with non-natural bases as anti-viral agents |
| WO2007041775A1 (en) * | 2005-10-10 | 2007-04-19 | The University Of Queensland | Cysteine protease inhibitors incorporating azide groups |
| MY150667A (en) | 2005-12-09 | 2014-02-28 | Gilead Pharmasset Llc | Antiviral nucleosides |
| CA2647276A1 (en) | 2006-04-04 | 2007-10-11 | F. Hoffmann-La Roche Ag | 3',5'-di-o-acylated nucleosides for hcv treatment |
| AU2007286754A1 (en) * | 2006-08-25 | 2008-02-28 | Viropharma Incorporated | Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto |
| SI2084174T1 (sl) | 2006-10-10 | 2013-10-30 | Gilead Pharmasset Llc | Priprava nukleozidov ribofuranozil pririmidinov |
| BRPI0718714B8 (pt) | 2006-11-09 | 2021-05-25 | Hoffmann La Roche | arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| AR069740A1 (es) * | 2007-11-29 | 2010-02-17 | Metabasis Therapeutics Inc | Compuestos nucleosidos antivirales |
| DK2234976T3 (da) | 2007-12-17 | 2013-06-24 | Hoffmann La Roche | Nye pyrazol-substituerede arylamider |
| ES2570628T3 (es) | 2007-12-17 | 2016-05-19 | Hoffmann La Roche | Nuevas arilamidas con sustitución imidazol |
| JP5456691B2 (ja) | 2007-12-17 | 2014-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | テトラゾール置換されたアリールアミド誘導体ならびにｐ２ｘ３及び／又はｐ２ｘ２／３プリン作動性受容体アンタゴニストとしてのその使用 |
| AU2008337660B2 (en) | 2007-12-17 | 2014-02-06 | F. Hoffmann-La Roche Ag | Triazole-substituted arylamide derivatives and their use as P2X3 and /or P2X2/3 purinergic receptor antagonists |
| EA020659B1 (ru) | 2008-04-23 | 2014-12-30 | Джилид Сайэнс, Инк. | 1'-замещённые карбануклеозидные аналоги для противовирусной терапии |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| EP2376514A2 (de) | 2008-12-23 | 2011-10-19 | Pharmasset, Inc. | Nukleosidanaloga |
| AR074897A1 (es) | 2008-12-23 | 2011-02-23 | Pharmasset Inc | Fosforamidatos de nucleosidos |
| PA8855801A1 (es) | 2008-12-23 | 2010-07-27 | Sintesis de nucleosidos de purina | |
| TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| ES2450891T3 (es) | 2009-06-22 | 2014-03-25 | F. Hoffmann-La Roche Ag | Bifenilamidas útiles como moduladores de receptores P2X3 y/o P2X2/3 |
| EP2445897B1 (de) | 2009-06-22 | 2014-03-19 | F.Hoffmann-La Roche Ag | Neue indazolarylamide als p2x3- und/oder p2x2/3-antagonisten |
| SG176640A1 (en) | 2009-06-22 | 2012-01-30 | Hoffmann La Roche | Novel oxazolone and pyrrolidinone-substituted arylamides |
| MX2012003126A (es) | 2009-09-21 | 2012-06-19 | Gilead Sciences Inc | Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos. |
| CA2780044A1 (en) | 2009-11-14 | 2011-05-19 | F. Hoffmann-La Roche Ag | Biomarkers for predicting rapid response to hcv treatment |
| RU2012127201A (ru) | 2009-12-02 | 2014-01-20 | Ф.Хоффманн-Ля Рош Аг | Биомаркеры для прогнозирования устойчивого ответа на лечение вируса гепатита с |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| US8859756B2 (en) | 2010-03-31 | 2014-10-14 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
| AP2013006665A0 (en) | 2010-07-19 | 2013-01-31 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| MX2013000744A (es) | 2010-07-22 | 2013-03-07 | Gilead Sciences Inc | Metodos y compuestos para tratar infecciones virales por paramyxoviridae. |
| ES2716158T3 (es) | 2010-11-30 | 2019-06-10 | Gilead Pharmasset Llc | 2'-spiro-nucleótidos para el tratamiento de hepatitis C |
| CN102850355B (zh) * | 2011-06-29 | 2015-02-11 | 四川大学 | 9-磺酰基-9h-嘌呤衍生物及其制备方法和用途 |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2861611B1 (de) | 2012-05-25 | 2016-07-13 | Janssen Sciences Ireland UC | Uracyl-spirooxetan-nukleoside |
| RS61767B1 (sr) | 2012-12-21 | 2021-05-31 | Janssen Biopharma Inc | 4'-fluor-nukleozidi, 4'-fluor-nukleotidi i njihovi analozi za lečenje hcv |
| WO2014120981A1 (en) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
| RU2534613C2 (ru) | 2013-03-22 | 2014-11-27 | Александр Васильевич Иващенко | Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения |
| PL3038601T3 (pl) | 2013-08-27 | 2020-08-24 | Gilead Pharmasset Llc | Formulacja złożona dwóch związków przeciwwirusowych |
| WO2015054465A1 (en) | 2013-10-11 | 2015-04-16 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| US10683321B2 (en) | 2013-12-18 | 2020-06-16 | Idenix Pharmaceuticals Llc | 4′-or nucleosides for the treatment of HCV |
| AU2015217221A1 (en) | 2014-02-13 | 2016-08-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
| WO2016003812A1 (en) | 2014-07-02 | 2016-01-07 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| JP6491486B2 (ja) * | 2015-01-29 | 2019-03-27 | 学校法人日本大学 | ８−アザ−３，７−ジデアザアデニンヌクレオシド誘導体、８−アザ−３，７−ジデアザアデニンヌクレオチド誘導体及びポリヌクレオチド誘導体ならびにプローブ |
| IL302877A (en) | 2015-03-06 | 2023-07-01 | Atea Pharmaceuticals Inc | Cell-D-2'-deoxy-2'-alpha-fluoro-2'-cell-C-modified-2-different-N6-purine modified nucleotides for the treatment of hepatitis C virus |
| MA42819A (fr) | 2015-09-16 | 2018-07-25 | Gilead Sciences Inc | Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae |
| EP3454862A4 (de) | 2016-05-10 | 2020-02-12 | C4 Therapeutics, Inc. | Spirocyclische degronimere für zielproteinabbau |
| CN109641874A (zh) | 2016-05-10 | 2019-04-16 | C4医药公司 | 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体 |
| CN109562107A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| US10202412B2 (en) | 2016-07-08 | 2019-02-12 | Atea Pharmaceuticals, Inc. | β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections |
| WO2018013937A1 (en) | 2016-07-14 | 2018-01-18 | Atea Pharmaceuticals, Inc. | Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
| KR20220146668A (ko) | 2016-09-07 | 2022-11-01 | 아테아 파마슈티컬즈, 인크. | Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드 |
| US10537590B2 (en) * | 2016-09-30 | 2020-01-21 | Boehringer Ingelheim International Gmbh | Cyclic dinucleotide compounds |
| GEP20237457B (en) | 2017-02-01 | 2023-01-10 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for treatment of hepatitis c virus |
| TW201836615A (zh) | 2017-03-14 | 2018-10-16 | 美商基利科學股份有限公司 | 治療貓冠狀病毒感染之方法 |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| US10675296B2 (en) | 2017-07-11 | 2020-06-09 | Gilead Sciences, Inc. | Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections |
| CN109384727B (zh) * | 2017-08-10 | 2023-07-28 | 中国科学院上海药物研究所 | 酞嗪酮类化合物、其制备方法、药物组合物及用途 |
| JP2021509907A (ja) | 2018-01-09 | 2021-04-08 | リガンド・ファーマシューティカルズ・インコーポレイテッド | アセタール化合物およびその治療的使用 |
| EP3773753A4 (de) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | Behandlung von hcv-infizierten patienten mit zirrhose |
| TWI789695B (zh) | 2020-01-27 | 2023-01-11 | 美商基利科學股份有限公司 | 治療sars cov-2感染之方法 |
| US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
| TWI785528B (zh) | 2020-03-12 | 2022-12-01 | 美商基利科學股份有限公司 | 1’-氰基核苷之製備方法 |
| EP4132651A1 (de) | 2020-04-06 | 2023-02-15 | Gilead Sciences, Inc. | Inhalationsformulierungen von 1'-cyansubstituierten carbanukleosidanaloga |
| EP4157272A1 (de) | 2020-05-29 | 2023-04-05 | Gilead Sciences, Inc. | Verfahren zur behandlung von remdesivir |
| BR112022026321A2 (pt) | 2020-06-24 | 2023-01-17 | Gilead Sciences Inc | Análogos de 1'-ciano nucleosídeo e usos dos mesmos |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| TW202400185A (zh) | 2022-03-02 | 2024-01-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
Family Cites Families (148)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US102414A (en) * | 1870-04-26 | Improvement in peat-machines | ||
| US225037A (en) * | 1880-03-02 | Apparatus for the manufacture of ice | ||
| US110718A (en) * | 1871-01-03 | Improvement in harvesters | ||
| US97461A (en) * | 1869-11-30 | Improvement in stump-extractors | ||
| US97462A (en) * | 1869-11-30 | Improved rrttit-slicer | ||
| US63622A (en) * | 1867-04-09 | Improvement in power looms | ||
| US63658A (en) * | 1867-04-09 | bobbins | ||
| US99072A (en) * | 1870-01-25 | Improvement in shoes for horses | ||
| US77587A (en) * | 1868-05-05 | Let i h | ||
| US110717A (en) * | 1871-01-03 | Improvement in car-wheel molds | ||
| US67877A (en) * | 1867-08-20 | Robert hitchcock | ||
| US67901A (en) * | 1867-08-20 | Washinoton | ||
| US83307A (en) * | 1868-10-20 | Improvement in wash-boilehs | ||
| US82574A (en) * | 1868-09-29 | Williams | ||
| US101535A (en) * | 1870-04-05 | Improvement in ornamental-scroll type | ||
| US2479A (en) * | 1842-03-04 | Machine for sizing papek | ||
| US87873A (en) * | 1869-03-16 | Perry prettyman | ||
| US2476A (en) * | 1842-02-28 | Machine for cutting meat and other substances | ||
| US50229A (en) * | 1865-10-03 | Improvement in cultivators | ||
| US72788A (en) * | 1867-12-31 | Charles d | ||
| US8841A (en) * | 1852-03-30 | Sice-httxieb | ||
| US55483A (en) * | 1866-06-12 | Improvement in pruning-hooks | ||
| US19363A (en) * | 1858-02-16 | Improved harpoon-and lance | ||
| US60400A (en) * | 1866-12-11 | Improved folding lounge | ||
| US225029A (en) * | 1880-03-02 | Magnetic grain-separator | ||
| US198171A (en) * | 1877-12-11 | Improvement in the mode of raising cream | ||
| US6007A (en) * | 1849-01-09 | Improvement in plows | ||
| US28013A (en) * | 1860-04-24 | Improved bullet-ladle | ||
| US147160A (en) * | 1874-02-03 | Improvement in seed-planters | ||
| US6002A (en) * | 1849-01-02 | Screw-wrench for grasping cylindrical forms | ||
| USRE29835E (en) * | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US3798209A (en) * | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| US4522811A (en) * | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5055394A (en) * | 1983-10-13 | 1991-10-08 | The United States Of America As Represented By The Secretary Of The Army | Nucleic acid probe and method for the rapid detection of typhoid fever bacteria |
| US5223263A (en) * | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
| JPH01501339A (ja) | 1986-10-14 | 1989-05-11 | ベックマン インスツルメンツ インコーポレーテッド | 改良された核酸ハイブリダイゼーション方法及びそれに用いるキット |
| EP0380558A4 (en) | 1987-09-22 | 1991-07-31 | The Regents Of The University Of California | Liposomal nucleoside analogues for treating aids |
| US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
| US5194654A (en) * | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
| JPH03148278A (ja) | 1989-11-02 | 1991-06-25 | Nippon Kayaku Co Ltd | 新規ヌクレオシド及びその製造法 |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| ATE194844T1 (de) * | 1990-04-06 | 2000-08-15 | Genelabs Tech Inc | Hepatitis c-virus-epitope |
| AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| WO1991018914A1 (en) | 1990-05-29 | 1991-12-12 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
| AU651835B2 (en) | 1990-06-13 | 1994-08-04 | Arnold Glazier | Phosphorous prodrugs |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
| US5149794A (en) * | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
| US6100024A (en) * | 1991-02-08 | 2000-08-08 | Promega Corporation | Methods and compositions for nucleic acid detection by target extension and probe amplification |
| EP0594677A4 (en) | 1991-07-12 | 1997-09-17 | Vical Inc | Antiviral liponucleosides: treatment of hepatitis b |
| TW224053B (de) * | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
| JPH05111389A (ja) | 1991-10-24 | 1993-05-07 | Sanyo Kokusaku Pulp Co Ltd | 新規な抗ウイルス剤 |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
| US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
| GB9226729D0 (en) * | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
| CA2156394A1 (en) * | 1993-02-24 | 1994-09-01 | Jui H. Wang | Compositions and methods of application of reactive antiviral polymers |
| ATE281647T1 (de) * | 1993-05-10 | 2004-11-15 | Chiron Corp | Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien |
| EP0746319A4 (de) | 1993-05-12 | 1997-11-05 | Karl Y Hostetler | Acyclovirderivate zur topischen verwendung |
| CA2167537A1 (en) * | 1993-07-19 | 1995-02-02 | Tsuneo Ozeki | Hepatitis c virus proliferation inhibitor |
| DE4415539C2 (de) * | 1994-05-03 | 1996-08-01 | Osama Dr Dr Med Omer | Pflanzen mit virustatischer und antiviraler Wirkung |
| DE4432623A1 (de) * | 1994-09-14 | 1996-03-21 | Huels Chemische Werke Ag | Verfahren zur Bleichung von wäßrigen Tensidlösungen |
| US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
| JP3786447B2 (ja) | 1995-03-31 | 2006-06-14 | エーザイ株式会社 | Ｃ型肝炎の予防・治療剤 |
| US5874565A (en) * | 1995-08-29 | 1999-02-23 | Washington University | Nucleic acids comprising a highly conserved novel 3 terminal sequence element of the hepatitis C virus |
| WO1997012033A1 (en) | 1995-09-27 | 1997-04-03 | Emory University | Recombinant hepatitis c virus rna replicase |
| EP0914421A2 (de) * | 1996-02-29 | 1999-05-12 | Immusol, Inc. | Ribozyme gegen den hepatitis c virus |
| US5830905A (en) * | 1996-03-29 | 1998-11-03 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
| JP3715027B2 (ja) * | 1996-05-07 | 2005-11-09 | シスメックス株式会社 | Ｃ型肝炎ウイルス感染症診断薬 |
| US5990276A (en) * | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
| US5891874A (en) * | 1996-06-05 | 1999-04-06 | Eli Lilly And Company | Anti-viral compound |
| US5837257A (en) * | 1996-07-09 | 1998-11-17 | Sage R&D | Use of plant extracts for treatment of HIV, HCV and HBV infections |
| JP3927630B2 (ja) | 1996-09-27 | 2007-06-13 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウイルス感染症の予防・治療剤 |
| US5922757A (en) * | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| PL187107B1 (pl) * | 1996-10-16 | 2004-05-31 | Icn Pharmaceuticals | L-nukleozydy monocykliczne, kompozycja farmaceutyczna zawierająca te związki oraz ich zastosowanie |
| KR100412480B1 (ko) | 1996-10-16 | 2003-12-31 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도 |
| US6436666B1 (en) * | 1996-10-17 | 2002-08-20 | Chiron Corporation | Protease regulator screening assay |
| UA79749C2 (en) | 1996-10-18 | 2007-07-25 | Vertex Pharma | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| IL119833A (en) * | 1996-12-15 | 2001-01-11 | Lavie David | Hypericum perforatum extracts for the preparation of pharmaceutical compositions for the treatment of hepatitis |
| JP2001514508A (ja) * | 1997-03-05 | 2001-09-11 | ユニバーシティー オブ ワシントン | Ｃ型肝炎ウイルスの複製を選択的に抑制する薬剤を同定するための新規なスクリーニング法 |
| US6004933A (en) * | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
| CN1136187C (zh) * | 1997-06-30 | 2004-01-28 | 莫茨股份公司 | 1-氨基烷基环己烷nmda受体拮抗剂 |
| IL134233A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues |
| AU2787199A (en) * | 1998-02-25 | 1999-09-15 | Emory University | 2'-fluoronucleosides |
| GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
| RU2211223C2 (ru) * | 1998-05-26 | 2003-08-27 | Ай-Си-Эн Фармасьютикалз, Инк. | Новые нуклеозиды, имеющие бициклическую сахарную группировку, и содержащие их олигонуклеотиды |
| US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
| US6492423B1 (en) | 1998-07-27 | 2002-12-10 | Istituto Di Ricerche Di Biologia Molecolare Pangeletti Spa | Diketoacid-derivatives as inhibitors of polymerases |
| US6323180B1 (en) * | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| JP2002537396A (ja) * | 1999-02-22 | 2002-11-05 | バイオケム ファーマ インコーポレイテッド | 抗ウィルス活性を有する［１，８］ナフチリジン誘導体 |
| DE19915178A1 (de) | 1999-04-03 | 2000-10-05 | Univ Mainz Johannes Gutenberg | Hepatitis C Virus Zellkultursystem |
| JP4202646B2 (ja) | 1999-08-30 | 2008-12-24 | ロッシュ ディアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−アザプリン化合物及びその使用 |
| WO2001032153A2 (en) * | 1999-11-04 | 2001-05-10 | Shire Biochem Inc. | Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
| PL364995A1 (en) | 2000-02-18 | 2004-12-27 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus |
| WO2001079246A2 (en) | 2000-04-13 | 2001-10-25 | Pharmasset, Ltd. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| EA200601591A1 (ru) * | 2000-05-26 | 2007-02-27 | Айденикс (Кайман) Лимитед | Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций |
| UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
| GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| CA2418199A1 (en) | 2000-07-21 | 2002-01-31 | Corvas International, Inc. | Peptides as ns3-serine protease inhibitors of hepatitis c virus |
| EP1303487A4 (de) | 2000-07-21 | 2005-11-23 | Schering Corp | Neue peptide als ns3-serin protease inhibitoren des hepatitis c virus |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| ATE491459T1 (de) * | 2000-10-18 | 2011-01-15 | Pharmasset Inc | Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation |
| US6650614B1 (en) | 2000-10-30 | 2003-11-18 | Cirrus Logic, Inc. | Optical disk pickup using current mode signal exchanges and systems and methods using the same |
| AU2002248147B2 (en) | 2000-11-20 | 2006-04-06 | Bristol-Myers Squibb Company | Hepatitis C tripeptide inhibitors |
| DE60138567D1 (de) | 2000-12-12 | 2009-06-10 | Schering Corp | Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus |
| WO2002048116A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
| WO2002048157A2 (en) | 2000-12-13 | 2002-06-20 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors |
| WO2002048165A2 (en) * | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| AU2002243791B2 (en) * | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
| GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| US7138376B2 (en) * | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
| EP1438054A4 (de) * | 2001-09-28 | 2006-07-26 | Idenix Cayman Ltd | Verfahren und zusammensetzungen zur behandlung von flaviviren und pestiviren mit 4'-modifiziertem nucleosid |
| MY151199A (en) | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
| US7217815B2 (en) * | 2002-01-17 | 2007-05-15 | Valeant Pharmaceuticals North America | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents |
| AU2002341942A1 (en) | 2002-01-17 | 2003-09-02 | Ribapharm Inc. | Sugar modified nucleosides as viral replication inhibitors |
| WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
| WO2003061385A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| GB0201179D0 (en) | 2002-01-18 | 2002-03-06 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US20040002476A1 (en) | 2002-02-14 | 2004-01-01 | Stuyver Lieven J. | Modified fluorinated nucleoside analogues |
| RU2004128943A (ru) | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
| AU2003218232A1 (en) * | 2002-03-12 | 2003-09-29 | Ariad Pharmaceuticals, Inc. | Peptide analogues and uses thereof |
| MXPA04010983A (es) * | 2002-05-06 | 2005-02-14 | Genelabs Tech Inc | Derivados de nucleosidos para tratar infecciones por el virus de la hepatitis c. |
| EP1551421A2 (de) | 2002-06-21 | 2005-07-13 | Merck & Co. Inc. | Nucleusidderivate als inhibitoren von viraler; rna-abhängiger rna-polymerase |
| EP1572945A2 (de) | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Nukleosidderivate als inhibitoren von viraler rna-abhängiger rna-polymerase |
| BR0312278A (pt) | 2002-06-28 | 2007-06-19 | Idenix Cayman Ltd | éster 2'-c-metil-3'-o-l-valina de ribofuranosil citidina para tratamento de infecções por flaviviridae |
| MXPA04012779A (es) | 2002-06-28 | 2005-08-19 | Idenix Cayman Ltd | Profarmacos de 2'- y 3'-nucleosido para tratar infecciones por flaviviridae. |
| BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
| AU2003269902A1 (en) | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| AU2003256619A1 (en) | 2002-07-24 | 2004-02-09 | Isis Pharmaceuticals, Inc. | Pyrrolopyrimidine thionucleoside analogs as antivirals |
| BR0313164A (pt) | 2002-08-01 | 2007-07-17 | Pharmasset Inc | compostos com o sistema biciclo[4.2.1] nonano para o tratamento de infecções por flaviviridae |
| AU2003263978A1 (en) | 2002-08-01 | 2004-02-23 | Board Of Trustees Of The Leland Stanford Junior University | 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections |
| US20040067877A1 (en) * | 2002-08-01 | 2004-04-08 | Schinazi Raymond F. | 2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections |
| RS20050175A (en) | 2002-08-23 | 2007-09-21 | Rigel Pharmaceuticals Inc., | Pyridyl substituted heterocycles useful for treating or preventing hcv infection |
| AU2003279797B2 (en) | 2002-09-30 | 2009-10-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
| AU2003274652A1 (en) * | 2002-10-23 | 2004-05-13 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
| AU2003287642A1 (en) | 2002-11-07 | 2004-06-03 | The Texas A And M University System | Process for solubilizing protein |
| DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
| US7598373B2 (en) | 2002-12-12 | 2009-10-06 | Idenix Pharmaceuticals, Inc. | Process for the production of 2-C-methyl-D-ribonolactone |
| PT1658302E (pt) * | 2003-07-25 | 2010-10-25 | Centre Nat Rech Scient | Análogos do nucleósido purina para o tratamento de doenças provocadas por flaviviridae incluindo hepatite c |
-
2004
- 2004-07-26 PT PT04744307T patent/PT1658302E/pt unknown
- 2004-07-26 EP EP04744307A patent/EP1658302B1/de active Active
- 2004-07-26 ES ES04744307T patent/ES2351603T3/es active Active
- 2004-07-26 PL PL04744307T patent/PL1658302T3/pl unknown
- 2004-07-26 US US10/900,008 patent/US20050075309A1/en not_active Abandoned
- 2004-07-26 CA CA2533367A patent/CA2533367C/en not_active Expired - Fee Related
- 2004-07-26 CN CNA2004800270217A patent/CN1852915A/zh active Pending
- 2004-07-26 KR KR1020067001534A patent/KR20060084845A/ko not_active Application Discontinuation
- 2004-07-26 JP JP2006520940A patent/JP2007501185A/ja active Pending
- 2004-07-26 WO PCT/IB2004/002703 patent/WO2005009418A2/en active Application Filing
- 2004-07-26 AU AU2004258750A patent/AU2004258750A1/en not_active Abandoned
- 2004-07-26 AT AT04744307T patent/ATE478886T1/de active
- 2004-07-26 DE DE602004028841T patent/DE602004028841D1/de active Active
- 2004-07-26 DK DK04744307.2T patent/DK1658302T3/da active
- 2004-07-26 BR BRPI0412849-4A patent/BRPI0412849A/pt not_active IP Right Cessation
- 2004-07-26 RU RU2006105640/04A patent/RU2006105640A/ru not_active Application Discontinuation
-
2006
- 2006-02-24 NO NO20060914A patent/NO20060914L/no not_active Application Discontinuation
-
2008
- 2008-11-13 US US12/270,795 patent/US8742101B2/en active Active
-
2014
- 2014-05-02 US US14/269,003 patent/US9186369B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20090169507A1 (en) | 2009-07-02 |
| JP2007501185A (ja) | 2007-01-25 |
| US9186369B2 (en) | 2015-11-17 |
| BRPI0412849A (pt) | 2006-09-26 |
| CA2533367C (en) | 2013-10-01 |
| EP1658302A2 (de) | 2006-05-24 |
| NO20060914L (no) | 2006-04-25 |
| WO2005009418A2 (en) | 2005-02-03 |
| ATE478886T1 (de) | 2010-09-15 |
| CA2533367A1 (en) | 2005-02-03 |
| ES2351603T3 (es) | 2011-02-08 |
| US20050075309A1 (en) | 2005-04-07 |
| AU2004258750A1 (en) | 2005-02-03 |
| CN1852915A (zh) | 2006-10-25 |
| WO2005009418A3 (en) | 2005-04-07 |
| KR20060084845A (ko) | 2006-07-25 |
| US20140234251A1 (en) | 2014-08-21 |
| DK1658302T3 (da) | 2010-11-22 |
| US8742101B2 (en) | 2014-06-03 |
| EP1658302B1 (de) | 2010-08-25 |
| RU2006105640A (ru) | 2007-09-10 |
| PL1658302T3 (pl) | 2011-03-31 |
| PT1658302E (pt) | 2010-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004028841D1 (de) | Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c | |
| WO2006000922A3 (en) | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae | |
| EA201490837A1 (ru) | Способы лечения hcv, включающие по меньшей мере два противовирусных агента прямого действия, рибавирин, но не интерферон | |
| BRPI0515896A (pt) | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus | |
| DE60234577D1 (de) | Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält | |
| NO20025600D0 (no) | Fremgangsmåter og sammensetninger for behandling av flavivirus og pestivirus | |
| TW200716095A (en) | Method of treating interferon non-responders using HCV protease inhibitor | |
| CY1109070T1 (el) | Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη | |
| BR9911076A (pt) | Uso de peg-ifn-alfa e ribavirina para o tratamento de hepatite c crÈnica | |
| TW200633995A (en) | Andrographolide derivatives to treat viral infections | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| BRPI0509140A (pt) | processos para o tratamento de infecção por hiv | |
| BRPI0415935A (pt) | combinações para tratamento de hcv | |
| CY1110437T1 (el) | Χρηση παραγωγων καστανοσπερμινης για την θεραπεια της ηπατιτιδας c | |
| NO20073632L (no) | Behandling av hepatitt C med interferon-beta i en asiatisk populasjon | |
| ATE481135T1 (de) | Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| BR0317095A (pt) | Uso de uma combinação contendo um inibidor da transcriptase reversa sem ser de nucleosìdeo (nnrti) com um inibidor citocromo p450, tal como inibidores da protease | |
| JP2003528919A5 (de) | ||
| BR0317539A (pt) | Métodos e composições para o tratamento de infecções por vìrus da herpes usando inibidores seletivos da ou ciclooxigenase-2 ou inibidores da ciclooxigenase-2 em combinação com agentes antivirais | |
| WO2002015664A3 (en) | Methods of preventing or treating west nile virus and other infections | |
| ATE545423T1 (de) | Mittel zur behandlung von lungenkrebs | |
| TW200740455A (en) | PEG-IFN alpha and ribavirin for HBV treatment | |
| WO2004096197A8 (en) | 5-aza-7-deazapurine nucleosides for treating flaviviridae | |
| DE60125377D1 (de) | Behandlung von hepatitis c mit thymosin, interferon und ribavirin |